A Phase 2 interventional study of Tildacerfont/Placebo in Congenital Adrenal Hyperplasia, sponsored by Spruce Biosciences. Terminated at 65 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-08.
Sponsored by Spruce Biosciences · Phase 2, Interventional, and Treatment
An investigation of the efficacy and safety of up to 70 weeks of treatment with Tildacerfont in subjects with classic CAH who have elevated biomarkers at baseline on their current GC regimen. Optional open label treatment extension period up to 240 weeks with 200mg Tildacerfont QD.
This is a study that will test the efficacy and safety of Tildacerfont. The first 12-weeks will be a double-blind, placebo controlled, dose ranging study. The following 58-weeks will assess the long term safety of Tildacerfont. Optional open label treatment extension period up to 240 weeks with 200mg Tildacerfont QD.
101 studies on the registry are indexed under Adrenal Hyperplasia, Congenital; 28 are open to participants now.
This study's enrollment of 96 is above the median of 37 across 50 interventional studies indexed under Adrenal Hyperplasia, Congenital.
Browse Adrenal Hyperplasia, Congenital studies →Spruce Biosciences is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Current treatment with dexamethasone as GC therapy for CAH
a. Prior treatment with dexamethasone is allowed as long as the transition to an alternative GC regimen (eg, HC, prednisone, or prednisolone) has resulted in a stable dose of GC replacement for ≥1 month before screening.
Has had a unstable medical condition, medically significant illness, or chronic disease occurring within 30 days of screening, including but not limited to:
Psychiatric conditions, including but not limited to bipolar disorder, schizophrenia, or schizoaffective disorders that are not effectively controlled on medication and may have an adverse impact on study compliance. Symptoms including hallucinations, delusions, and psychosis are exclusionary. Additionally:
Has clinically significant abnormal or clinical laboratory results. Abnormal results that must be reviewed and discussed with the Medical Monitor to determine eligibility for this study include but are not limited to:
Use of the following drugs from 30 days or 5 half-lives (whichever is longer) before Day 1 to the end of the study:
i. Moderate to strong inhibitors and/or inducers of ii. Sensitive substrates or narrow-therapeutic-range substrates of CYP3A4 (except hormonal containing ≤35 μg ethinyl estradiol) iii. Sensitive substrates or narrow-therapeutic-range substrates of BCRP (except those that can be administered QD in the morning, separated by approximately 10 hours from evening administration of study drug)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tildacerfont administered daily via oral tablet for 12 weeks at dose level 1
Drug: Tildacerfont/Placebo
Tildacerfont administered daily via oral tablet for 12 weeks at dose level 2
Drug: Tildacerfont/Placebo
Tildacerfont administered daily via oral tablet for 70 weeks at dose level 3
Drug: Tildacerfont/Placebo
Placebo administered daily via oral tablet for 12 weeks.
Drug: Tildacerfont/Placebo
Tablet, administered daily
Also known as: SPR001
To Evaluate the Effect of Tildacerfont in Reducing A4 in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Over 12 Weeks
Assessment of dose response for change from baseline in log A4 after 12 weeks on double-blind placebo-controlled treatment (Week 18)
Time frame: Baseline and 12 weeks of treatment (Week 18)
To Evaluate the Effect of Tildacerfont in Reducing A4 in Participants With Classic CAH Over 12 Weeks
Absolute change from baseline in A4 as determined via application of the delta theorem to the log scale analysis results after 12 weeks on double-blind, placebo-controlled treatment (Week 18). Results show mean Treatment Effect of Dose vs Placebo. A negative value represents a reduction in absolute concentration compared to baseline.
Time frame: 12 weeks
To Evaluate the Effect of Tildacerfont in Reducing A4 in Participants With Classic CAH Over 12 Weeks
Change from baseline in A4 as assessed on the log scale after 12 weeks on double-blind, placebo-controlled treatment (Week 18). Results show mean % of Treatment Effect of Dose vs Placebo. A negative value represents a % reduction from baseline.
Time frame: 12 weeks
To Evaluate the Effect of Tildacerfont in Reducing 17-OHP in Participants With Classic CAH Over 12 Weeks
Change from baseline in 17-OHP as assessed on the log scale after 12 weeks on double-blind, placebo-controlled treatment (Week 18). A negative value represents a % reduction from baseline.
Time frame: 12 weeks
To Evaluate the Effect of Tildacerfont in Reducing 17-OHP in Participants With Classic CAH Over 12 Weeks
Absolute change from baseline in 17-OHP as determined via application of the delta theorem to the log scale analysis results after 12 weeks on double-blind, placebo-controlled treatment (Week 18). Results show mean Treatment Effect of Dose vs Placebo. A negative value represents a reduction in absolute concentration compared to baseline.
Time frame: 12 weeks
96 participants participated in Part A , 86 of those participants continued into Part B, and 57 of these participants then entered Part C
| Milestone | Period 1: Placebo | Period 2: Part A 50 mg | Period 2: Part A 100 mg | Period 2: Part A 200 mg | Period 3: Part B 50 mg | Period 3: Part B 100 mg | Period 3: Part B 200 mg | Period 4: Part C |
|---|---|---|---|---|---|---|---|---|
| Started | 24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Period 1: Placebo | Period 2: Part A 50 mg | Period 2: Part A 100 mg | Period 2: Part A 200 mg | Period 3: Part B 50 mg | Period 3: Part B 100 mg | Period 3: Part B 200 mg | Period 4: Part C |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 24 | 24 | 24 | 0 | 0 | 0 | 0 |
| Completed | 0 | 20 | 21 | 21 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 4 | 3 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Period 1: Placebo | Period 2: Part A 50 mg | Period 2: Part A 100 mg | Period 2: Part A 200 mg | Period 3: Part B 50 mg | Period 3: Part B 100 mg | Period 3: Part B 200 mg | Period 4: Part C |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 1 | 44 | 41 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 33 | 26 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 11 | 15 | 0 |
| Withdrew: Study terminated | 0 | 0 | 0 | 0 | 1 | 10 | 13 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 |
| Milestone | Period 1: Placebo | Period 2: Part A 50 mg | Period 2: Part A 100 mg | Period 2: Part A 200 mg | Period 3: Part B 50 mg | Period 3: Part B 100 mg | Period 3: Part B 200 mg | Period 4: Part C |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 57 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 38 |
| Withdrew: Study terminated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 30 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Site terminated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
Assessment of dose response for change from baseline in log A4 after 12 weeks on double-blind placebo-controlled treatment (Week 18)
| log(ng/dL) | Placebo | Tildacerfont 50 mg | Tildacerfont 100 mg | Tildacerfont 200 mg |
|---|---|---|---|---|
| To Evaluate the Effect of Tildacerfont in Reducing A4 in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Over 12 Weeks | 38.7 ± 307.38 | -49.0 ± 449.02 | 147.2 ± 661.2 | -10.4 ± 408.68 |
Absolute change from baseline in A4 as determined via application of the delta theorem to the log scale analysis results after 12 weeks on double-blind, placebo-controlled treatment (Week 18). Results show mean Treatment Effect of Dose vs Placebo. A negative value represents a reduction in absolute concentration compared to baseline.
| ng/dL | Placebo | Tildacerfont 50 mg | Tildacerfont 100 mg | Tildacerfont 200 mg |
|---|---|---|---|---|
| To Evaluate the Effect of Tildacerfont in Reducing A4 in Participants With Classic CAH Over 12 Weeks | 0 ± 0 | -29.5 ± 106.26 | 39.1 ± 108.66 | -23.2 ± 107.72 |
Change from baseline in A4 as assessed on the log scale after 12 weeks on double-blind, placebo-controlled treatment (Week 18). Results show mean % of Treatment Effect of Dose vs Placebo. A negative value represents a % reduction from baseline.
| percentage | Placebo | Tildacerfont 50 mg | Tildacerfont 100 mg | Tildacerfont 200 mg |
|---|---|---|---|---|
| To Evaluate the Effect of Tildacerfont in Reducing A4 in Participants With Classic CAH Over 12 Weeks | 0 (0 to 0) | -3.3 (-23.7 to 22.7) | 4.3 (-17.4 to 31.8) | -2.6 (-23.3 to 23.9) |
Change from baseline in 17-OHP as assessed on the log scale after 12 weeks on double-blind, placebo-controlled treatment (Week 18). A negative value represents a % reduction from baseline.
| percent change | Placebo | Tildacerfont 50 mg | Tildacerfont 100 mg | Tildacerfont 200 mg |
|---|---|---|---|---|
| To Evaluate the Effect of Tildacerfont in Reducing 17-OHP in Participants With Classic CAH Over 12 Weeks | 215.6 ± 6165.61 | 644.2 ± 6580.01 | 3564.6 ± 7490.8 | -753.7 ± 5698.97 |
Absolute change from baseline in 17-OHP as determined via application of the delta theorem to the log scale analysis results after 12 weeks on double-blind, placebo-controlled treatment (Week 18). Results show mean Treatment Effect of Dose vs Placebo. A negative value represents a reduction in absolute concentration compared to baseline.
| ng/dL | Placebo | Tildacerfont 50 mg | Tildacerfont 100 mg | Tildacerfont 200 mg |
|---|---|---|---|---|
| To Evaluate the Effect of Tildacerfont in Reducing 17-OHP in Participants With Classic CAH Over 12 Weeks | 0 ± 0 | 355.9 ± 2179.63 | 22.6 ± 2120.47 | -250.8 ± 2153.59 |
Collected over 60 weeks (12 weeks Part A, 12 weeks Part B, 46 weeks Part C). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1: Placebo | 0/24 (0%) | 0/24 (0%) | 17/24 (70.8%) |
| Period 2: Part A 50 mg | 0/24 (0%) | 1/24 (4.2%) | 16/24 (66.7%) |
| Period 2: Part A 100 mg | 0/24 (0%) | 1/24 (4.2%) | 20/24 (83.3%) |
| Period 2: Part A 200 mg | 0/24 (0%) | 0/24 (0%) | 16/24 (66.7%) |
| Period 3: Part B 50 mg | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Period 3: Part B 100 mg | 0/44 (0%) | 2/44 (4.5%) | 26/44 (59.1%) |
| Period 3: Part B 200 mg | 0/41 (0%) | 0/41 (0%) | 17/41 (41.5%) |
| Period 4: Part C | 0/57 (0%) | 1/57 (1.8%) | 38/57 (66.7%) |
| Event | Period 1: Placebo | Period 2: Part A 50 mg | Period 2: Part A 100 mg | Period 2: Part A 200 mg | Period 3: Part B 50 mg | Period 3: Part B 100 mg | Period 3: Part B 200 mg | Period 4: Part C |
|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | — | 1/24 | 0/24 | 0/24 | 0/1 | 0/44 | 0/41 | 0/57 |
| PyrexiaNervous system disorders | — | 0/24 | 1/24 | 0/24 | 0/1 | 0/44 | 0/41 | 0/57 |
| Status EpilepticusNervous system disorders | — | 0/24 | 1/24 | 0/24 | 0/1 | 0/44 | 0/41 | 0/57 |
| Staphylococcal PneumoniaInfections and infestations | — | 0/24 | 0/24 | 0/24 | 0/1 | 1/44 | 0/41 | 0/57 |
| Nasal septum deviationMusculoskeletal and connective tissue disorders | — | 0/24 | 0/24 | 0/24 | 0/1 | 1/44 | 0/41 | 0/57 |
| SyncopeNervous system disorders | — | 0/24 | 0/24 | 0/24 | 0/1 | 0/44 | 0/41 | 1/57 |
| DiarrheaGastrointestinal disorders | — | 0/24 | 0/24 | 0/24 | 0/1 | 0/44 | 0/41 | 1/57 |
| EnteritisGastrointestinal disorders | — | 0/24 | 0/24 | 0/24 | 0/1 | 0/44 | 0/41 | 1/57 |
| Event | Period 1: Placebo | Period 2: Part A 50 mg | Period 2: Part A 100 mg | Period 2: Part A 200 mg | Period 3: Part B 50 mg | Period 3: Part B 100 mg | Period 3: Part B 200 mg | Period 4: Part C |
|---|---|---|---|---|---|---|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 1/24 | 0/24 | 5/24 | 1/24 | 0/1 | 1/44 | 1/41 | 2/57 |
| HeadacheNervous system disorders | 2/24 | 4/24 | 5/24 | 2/24 | 0/1 | 1/44 | 0/41 | 4/57 |
| NasopharyngitisInfections and infestations | 1/24 | 0/24 | 2/24 | 1/24 | 0/1 | 5/44 | 0/41 | 10/57 |
| PyrexiaGeneral disorders | 0/24 | 3/24 | 3/24 | 1/24 | 0/1 | 3/44 | 0/41 | 5/57 |
| AstheniaGeneral disorders | 1/24 | 1/24 | 1/24 | 3/24 | 0/1 | 1/44 | 1/41 | 0/57 |
| FatigueGeneral disorders | 0/24 | 3/24 | 0/24 | 0/24 | 0/1 | 3/44 | 0/41 | 3/57 |
| NauseaGastrointestinal disorders | 0/24 | 1/24 | 3/24 | 0/24 | 0/1 | 0/44 | 0/41 | 1/57 |
| VomitingGastrointestinal disorders | 0/24 | 1/24 | 3/24 | 0/24 | 0/1 | 0/44 | 0/41 | 4/57 |
| AcneSkin and subcutaneous tissue disorders | 1/24 | 2/24 | 0/24 | 3/24 | 0/1 | 0/44 | 1/41 | 3/57 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/24 | 3/24 | 0/24 | 1/24 | 0/1 | 0/44 | 0/41 | 0/57 |
The ITT Analysis Set included all randomized participants regardless of Treatment Period eligibility or completion. The ITT Analysis Set was the basis for demographics, baseline characteristics, and efficacy analyses.
| Age, Continuous(years) | Placebo | Tildacerfont 50 mg | Tildacerfont 100 mg | Tildacerfont 200 mg | Total |
|---|---|---|---|---|---|
| Mean | 33.5 ± 12.03 | 29.1 ± 11.55 | 31.5 ± 8.29 | 35.1 ± 11.36 | 32.3 ± 10.81 |
| Sex: Female, Male(Participants) | Placebo | Tildacerfont 50 mg | Tildacerfont 100 mg | Tildacerfont 200 mg | Total |
|---|---|---|---|---|---|
| Female | 12 | 11 | 12 | 16 | 51 |
| Male | 12 | 13 | 12 | 8 | 45 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Tildacerfont 50 mg | Tildacerfont 100 mg | Tildacerfont 200 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 3 | 4 |
| Not Hispanic or Latino | 23 | 24 | 24 | 21 | 92 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Tildacerfont 50 mg | Tildacerfont 100 mg | Tildacerfont 200 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 2 | 1 | 4 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 21 | 22 | 22 | 19 | 84 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 | 2 |
| BMI(kg/m^2) | Placebo | Tildacerfont 50 mg | Tildacerfont 100 mg | Tildacerfont 200 mg | Total |
|---|---|---|---|---|---|
| Mean | 31.46 ± 9.29 | 31.27 ± 7.675 | 30.98 ± 7.521 | 30.25 ± 4.453 | 30.99 ± 7.23 |
| Waist Circumference(cm) | Placebo | Tildacerfont 50 mg | Tildacerfont 100 mg | Tildacerfont 200 mg | Total |
|---|---|---|---|---|---|
| Mean | 95.8 ± 17.074 | 98.78 ± 19.135 | 97.98 ± 19.148 | 99.31 ± 12.407 | 97.968 ± 16.941 |
| Daily dose of Glucocorticoid(mg in hydrocortisone equivalent(s)) | Placebo | Tildacerfont 50 mg | Tildacerfont 100 mg | Tildacerfont 200 mg | Total |
|---|---|---|---|---|---|
| Mean | 26.9 ± 7.59 | 29.1 ± 10.83 | 25.4 ± 6.71 | 26.7 ± 8.94 | 27.025 ± 8.518 |
| Glucocorticoid BSA Based Dose(mg in hydrocortisone equivalent(s)/m^2) | Placebo | Tildacerfont 50 mg | Tildacerfont 100 mg | Tildacerfont 200 mg | Total |
|---|---|---|---|---|---|
| Mean | 13.97 ± 4.198 | 14.62 ± 4.880 | 13.52 ± 4.117 | 14.21 ± 12.5 | 14.08 ± 6.424 |
12 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2020 to primary completion in Feb 2024, 41 months.
Results were first posted in Jul 2025, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Adrenal Hyperplasia, Congenital →
Spruce Biosciences